Close Menu

SiMoA

Quanterix and BioMérieux recently announced a partnership giving BioMérieux worldwide exclusive rights to Quanterix's Single Molecule Array, or SiMoA, technology for clinical assay development and industrial applications.

Quanterix is now "shifting from an R&D phase to a commercial phase" as it prepares to launch its Simoa platform next year.

By Adam Bonislawski
Scientists at the Forsyth Institute, Beth Israel Deaconess Medical Center, and biomarker firm Quanterix announced this week a collaboration to evaluate protein biomarkers for tuberculosis.

Quanterix said this week that it has received an investment of an undisclosed amount from In-Q-Tel, a non-profit investment firm that delivers technology to the US intelligence community.

The figure comes from a report commissioned by proteomics firm Proteome Sciences, which, like a number of other protein biomarker firms including Quanterix, Rules-Based Medicine, and NextGen Sciences, has made AD a significant focus of its R&D and commercialization efforts.

The firm is currently developing a research-use-only version of the instrument that it expects to launch in 2013 with an FDA-approved version coming sometime after that. It plans to manufacture the RUO device through an outside vendor because most of its parts are off-the-shelf.

Cambridge, Mass.-based Quanterix will use the funds to develop its AccuPSA prostate cancer test, which runs on its single molecule array, or SiMoA, platform.

Pages

At a meeting this week, researchers and others discussed the regulatory oversight needed for germline genome editing.

The US Food and Drug Administration has asked questions about Myriad Genetics' GeneSight test, according to Bloomberg.

Researchers report that neutrophil extracellular traps appear to binds gallstones together, according to New Scientist.

In Science this week: approach to infer genotype-by-environment interaction from genetic variants associated with phenotypic variability, and more.